Adjuvant therapy of gastrointestinal stromal tumors

Vadim P. Koshenkov, Steven Rodgers

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose of review: The treatment of gastrointestinal stromal tumors (GISTs) with tyrosine kinase inhibitors (TKIs), such as imatinib and sunitinib, has produced improved outcomes and survival. However, patients with high-risk tumors still have unacceptably high rates of recurrence and disease progression. In the current review, we examine the various strategies for optimizing the treatment of GISTs. Recent findings: Extended duration of treatment (36 months) with adjuvant imatinib resulted in improved recurrence-free survival and overall survival, whereas discontinuation of the TKI led to relapse of disease in most high-risk patients. High-dose therapy of imatinib was beneficial for patients with KIT exon 9 mutations. Patients with KIT exon 11 mutations experienced the most improvement in outcomes from adjuvant imatinib. Summary: The extended duration of TKI treatment, dose optimization, mutation status, and the effects of TKI discontinuation have recently been examined in more detail. As our understanding of TKI therapy grows, an individualized approach to each patient should lead to better outcomes.

Original languageEnglish
Pages (from-to)414-418
Number of pages5
JournalCurrent Opinion in Oncology
Volume24
Issue number4
DOIs
StatePublished - Jul 1 2012

Fingerprint

Gastrointestinal Stromal Tumors
Protein-Tyrosine Kinases
Recurrence
Mutation
Survival
Exons
Therapeutics
Disease Progression
Imatinib Mesylate
Neoplasms

Keywords

  • adjuvant
  • dose
  • gastrointestinal stromal tumors
  • imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant therapy of gastrointestinal stromal tumors. / Koshenkov, Vadim P.; Rodgers, Steven.

In: Current Opinion in Oncology, Vol. 24, No. 4, 01.07.2012, p. 414-418.

Research output: Contribution to journalArticle

Koshenkov, Vadim P. ; Rodgers, Steven. / Adjuvant therapy of gastrointestinal stromal tumors. In: Current Opinion in Oncology. 2012 ; Vol. 24, No. 4. pp. 414-418.
@article{d7efce76843543c8a06b6835ceb1a5a6,
title = "Adjuvant therapy of gastrointestinal stromal tumors",
abstract = "Lippincott Williams & Wilkins.",
keywords = "adjuvant, dose, gastrointestinal stromal tumors, imatinib",
author = "Koshenkov, {Vadim P.} and Steven Rodgers",
year = "2012",
month = "7",
day = "1",
doi = "10.1097/CCO.0b013e328353d774",
language = "English",
volume = "24",
pages = "414--418",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Adjuvant therapy of gastrointestinal stromal tumors

AU - Koshenkov, Vadim P.

AU - Rodgers, Steven

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Lippincott Williams & Wilkins.

AB - Lippincott Williams & Wilkins.

KW - adjuvant

KW - dose

KW - gastrointestinal stromal tumors

KW - imatinib

UR - http://www.scopus.com/inward/record.url?scp=84862147870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862147870&partnerID=8YFLogxK

U2 - 10.1097/CCO.0b013e328353d774

DO - 10.1097/CCO.0b013e328353d774

M3 - Article

VL - 24

SP - 414

EP - 418

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -